Mr. Todd Shapiro reports

RED LIGHT HOLLAND ANNOUNCES FILAMENT HEALTH OBTAINS FINAL ORDER FOR PROPOSED ARRANGEMENT

Further to Red Light Holland Corp. and Filament Health Corp.'s joint press releases dated March 10, 2026, March 23, 2026, and April 27, 2026, the Supreme Court of British Columbia has issued a final order approving the previously announced acquisition by Red Light of all the issued and outstanding common shares of Filament, pursuant to a statutory plan of arrangement under the Business Corporations Act (British Columbia).

Completion of the arrangement remains subject to customary conditions and certain regulatory approvals. It is anticipated that the arrangement will be completed on or about April 29, 2026, in accordance with the terms of the arrangement agreement dated March 10, 2026, between Red Light and Filament.

Further information regarding the arrangement is provided in the management information circular for Filament's shareholder meeting held on April 24, 2026, which is available under Filament's profile on SEDAR+ and on Filament's website.

About Red Light Holland Corp.

Red Light Holland is an Ontario-based company advancing a focused strategy within the legal psychedelic sector, centred on voluntary data collection and research and development initiatives designed to expand naturally occurring drug development, understanding of psilocybin use and consumer experiences. In parallel, the company operates commercial activities across Europe and North America, including psilocybin truffle sales in the Dutch legal market and mushroom home grow kits offered through business-to-busines and direct-to-consumer channels in compliance with applicable laws.

About Filament Health Corp.

Filament Health is a clinical-stage natural psychedelic drug development company. Filament believes that safe, standardized, naturally derived psychedelic medicines can improve the lives of many, and its mission is to see them in the hands of everyone who needs them as soon as possible. Filament's platform of proprietary intellectual property enables the discovery, development and delivery of natural psychedelic medicines for clinical development. Filament is paving the way with the first ever natural psychedelic drug candidates.

We seek Safe Harbor.